Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies

Current Opinion in Immunology

Volumn 23, Issue 3, 2011, Pages 383-390

  Verkoczy, Laurent ^a   Kelsoe, Garnett ^a   Moody, M Anthony ^a   Haynes, Barton F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

ANTIBODY DETECTION; ANTIBODY ISOLATION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; B LYMPHOCYTE; COMPLEMENTARITY DETERMINING REGION; DRUG DESIGN; GENE TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; NONHUMAN; ONTOGENY; REVIEW; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 79957726572     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2011.04.003     Document Type: Review

References (74)

1. Plotkin S.A. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010, 17:1055-1065.
2. McMichael A.J., Borrow S., Tomaras G.D., Goonetilleke N., Haynes B.F. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010, 10:11-23.
3. Richman D.D., Wrin T., Little S.J., Petropoulos C.J. Rapid evolution of the neutralizing antibody response to hiv type 1 infection. Proc Natl Acad Sci USA 2003, 100:4144-4149.
4. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
5. Keele B.F., Giorgi E.E., Salazar-Gonzalez J.F., Decker J.M., Pham K.T., Salazar M.G., Sun C., Grayson T., Wang S., Li H., et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008, 105:7552-7557.
6. Mascola J.R., Montefiori D.C. The role of antibodies in HIV vaccines. Annu Rev Immunol 2010, 28:413-444.
7. Hessell A.J., Poignard P., Hunter M., Hangartner L., Tehrani D.M., Bleeker W.K., Parren P.W., Marx P.A., Burton D.R. Effective, low-titer antibody protection against low-dose repeated mucosal shiv challenge in macaques. Nat Med 2009, 15:951-954.
8. Hessell A.J., Rakasz E.G., Poignard P., Hangartner L., Landucci G., Forthal D.N., Koff W.C., Watkins D.I., Burton D.R. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009, 5:e1000433.
9. Hessell A.J., Rakasz E.G., Tehrani D.M., Huber M., Weisgrau K.L., Landucci G., Forthal D.N., Koff W.C., Poignard P., Watkins D.I., Burton D.R. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2010, 84:1302-1313.
10. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000, 6:207-210.
11. McElrath M.J., Haynes B.F. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010, 33:542-554.
12. Binley J.M., Ban Y.E., Crooks E.T., Eggink D., Osawa K., Schief W.R., Sanders R.W. Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol 2010, 84:5637-5655.
13. Frey G., Peng H., Rits-Volloch S., Morelli M., Cheng Y., Chen B. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci USA 2008, 105:3739-3744.
14. Labrijn A.F., Poignard P., Raja A., Zwick M.B., Delgado K., Franti M., Binley J.M., Vivona V., Grundner C., Huang C.C., et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003, 77:10557-10565.
15. Schief W.R., Ban Y.E., Stamatatos L. Challenges for structure-based HIV vaccine design. Curr Opin HIV AIDS 2009, 4:431-440.
16. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., Steenbeke T.D., Venturi M., Chaiken I., Fung M., et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002, 420:678-682.
17. Stamatatos L., Morris L., Burton D.R., Mascola J.R. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat Med 2009, 15:866-870.
18. Mikell I., Sather D.N., Kalams S.A., Altfeld M., Alter G., Stamatatos L. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 2011, 7:e1001251.
19. Haynes B.F., Fleming J., St Clair E.W., Katinger H., Stiegler G., Kunert R., Robinson J., Scearce R.M., Plonk K., Staats H.F., et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308:1906-1908.
20. Haynes B.F., Moody M.A., Verkoczy L., Kelsoe G., Alam S.M. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum Antibodies 2005, 14:59-67.
21. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., Sawyer L.S., Hendry R.M., Dunlop N., Nara P.L., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266:1024-1027.
22. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993, 67:6642-6647.
23. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001, 17:1757-1765.
24. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996, 70:1100-1108.
25. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., Parren P.W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001, 75:10892-10905.
26. Bonsignori M., Hwang K.-K., Chen X., Tsao C.-Y., Bilska M., Fang W., Marshall D., Whitesides J.F., Crump J.A., Noel S., et al. Immunoregulation of HIV-1 broadly neutralizing antibody responses: deciphering maturation paths for antibody induction. AIDS Res Hum Retroviruses 2010, 26. A-4.52.
27. Corti D., Langedijk J.P., Hinz A., Seaman M.S., Vanzetta F., Fernandez-Rodriguez B.M., Silacci C., Pinna D., Jarrossay D., Balla-Jhagjhoorsingh S., et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 2010, 5:e8805.
28. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., et al. Broad and potent neutralizing antibodies from an african donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
29. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., Zhou T., Schmidt S.D., Wu L., Xu L., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
30. Zhou T, Georgiev I, Wu X, Z.Y. Y, Dai K, A. F, Kwon YD, Scheid JF, Shi W, Xu L, Yang Y et al.: Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329:811-817.
31. Zhu Z., Qin H., Chen W., Zhao Q., Fouda G., Schutte R., Shen X., Liao L., Ofek G., Owens J., et al. New broadly neutralizing human monoclonal antibodies targeting the 2F5 epitope. AIDS Res Hum Retroviruses 2010, 26. A-5.4.
32. Basten A., Silveira P.A. B-cell tolerance: mechanisms and implications. Curr Opin Immunol 2010, 22:566-574.
33. Meffre E., Wardemann H. B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol 2008, 20:632-638.
34. Wardemann H., Yurasov S., Schaefer A., Young J.W., Meffre E., Nussenzweig M.C. Predominant autoantibody production by early human B cell precursors. Science 2003, 301:1374-1377.
35. Ivanov I.I., Schelonka R.L., Zhuang Y., Gartland G.L., Zemlin M., Schroeder H.W. Development of the expressed Ig CDR-H3 repertoire is marked by focusing of constraints in length, amino acid use, and charge that re first established in early B cell progenitors. J Immunol 2005, 174:7773-7780.
36. Meffre E., Milili M., Blanco-Betancourt C., Antunes H., Nussenzweig M.C., Schiff C. Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. J Clin Invest 2001, 108:879-886.
37. Shiokawa S., Mortari F., Lima J., Nuñez C., Bertrand Fr, Kirkham P.M., Zhu S., Dasanayake A.P., Schroeder H.J. IgM heavy chain complementarity-determining region 3 diversity is constrained by genetic and somatic mechanisms until two months after birth. J Immunol 1999, 162:6060-6070.
38. Li H., Jiang Y., Prak E.L., Radic M., Weigert M. Editors and editing of anti-DNA receptors. Immunity 2001, 15:947-957.
39. Chen C., Nagy Z., Radic M.Z., Hardy R.R., Huszar D., Camper S.A., Weigert M. The site and stage of anti-DNA B-cell deletion. Nature 1995, 373:252-255.
40. Chen C., Prak E.L., Weigert M. Editing disease-associated autoantibodies. Immunity 1997, 6:97-105.
41. Hardy R.R. B-1 B cell development. J Immunol 2006, 177:2749-2754.
42. Keenan R.A., De Riva A., Corleis B., Hepburn L., Licence S., Winkler T.H., Mårtensson I.L. Censoring of autoreactive b cell development by the pre-B cell receptor. Science 2008, 321:696-699.
43. Vettermann C., Jäck H.M. The pre-B cell receptor: turning autoreactivity into self-defense. Trends Immunol 2010, 31:176-183.
44. von Boehmer H., Melchers F. Checkpoints in lymphocyte development and autoimmune disease. Nat Immunol 2010, 11:14-20.
45. Decker D.J., Kline G.H., Hayden T.A., Zaharevitz S.N., Klinman N.R. Heavy chain V gene-specific elimination of B cells during the pre-B cell to B cell transition. J Immunol 1995, 154:4924-4935.
46. Kline G.H., Hartwell L., Beck-Engeser G.B., Keyna U., Zaharevitz S., Klinman N.R., Jäck H.M. Pre-B cell receptor-mediated selection of pre-B cells synthesizing functional mu heavy chains. J Immunol 1998, 161:1608-1618.
47. Martin F., Kearney J.F. Marginal-zone B cells. Nat Rev Immunol 2002, 2:323-335.
48. Verkoczy L., Diaz M., Holl T.M., Ouyang Y.B., Bouton-Verville H., Alam S.M., Liao H.X., Kelsoe G., Haynes B.F. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci USA 2010, 107:181-186.
49. Shlomchik M.J. Sites and stages of autoreactive B cell activation and regulation. Immunity 2008, 28:18-28.
50. Verkoczy L., Bouton-Verville H., Hutchinson J., Scearce R.M., Liao H.-X., Hwang K.-K., Haynes B.F. Role of immunoglobulin light chain usage and MPER specificity in counterselecting B cells expressing the broadly neutralizing antibody 2F5. AIDS Res Hum Retroviruses 2010, 26. A-4.55.
51. Verkoczy L., Chen Y., Bouton-Verville H., Hutchinson J., Scearce R.M., Holl T.M., Hwang K.-K., Kelsoe G., Haynes B.F. Clonal deletion of MPER antibodies: implications for vaccine design. 18th CROI: Anti-HIV Symposium 2011, A-63.
52. Holl TM, Kuraoka M, Liao D, Verkoczy L, Moody MA, Alam M, Liao HX, Haynes BF, G.H. K: Generation of antibody responses to HIV-1 membrane proximal external region (MPER) antigen. Retrovirology 2009, 6:A-4.26.
53. Kaye B.R. Rheumatologic manifestations of infection with human immunodeficiency virus (HIV). Ann Intern Med 1989, 111:158-167.
54. Palacios R., Santos J. Human immunodeficiency virus infection and systemic lupus erythematosus. Int J STD AIDS 2004, 15:277-278.
55. Palacios R., Santos J., Valdivielso P., Márquez M. Human immunodeficiency virus infection and systemic lupus erythematosus. An unusual case and a review of the literature. Lupus 2002, 11:60-63.
56. Verkoczy L., Moody M.A., Holl T.M., Bouton-Verville H., Scearce R., Hutchinson J., Alam S.M., Kelsoe G., Haynes B. Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region. PLoS ONE 2009, 4:e7215.
57. Holl T.M., Haynes B.F., Kelsoe G. Stromal cell independent B cell development in vitro: generation and recovery of autoreactive clones. J Immunol Methods 2010, 354:53-67.
58. Alam S.M., Morelli M., Dennison S.M., Liao H.X., Zhang R., Xia S.M., Rits-Volloch S., Sun L., Harrison S.C., Haynes B.F., Chen B. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci USA 2009, 106:20234-20239.
59. Ofek G., McKee K., Yang Y., Yang Z.Y., Skinner J., Guenaga F.J., Wyatt R., Zwick M.B., Nabel G.J., Mascola J.R., Kwong P.D. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J Virol 2010, 84:2955-2962.
60. Scherer E.M., Leaman D.P., Zwick M.B., McMichael A.J., Burton D.R. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc Natl Acad Sci USA 2010, 107:1529-1534.
61. Klein J.S., Bjorkman P.J. Few and far between: how HIV may be evading antibody avidity. PLoS Pathog 2010, 6:e1000908.
62. Mouquet H., Scheid J.F., Zoller M.J., Krogsgaard M., Ott R.G., Shukair S., Artyomov M.N., Pietzsch J., Connors M., Pereyra F., et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010, 467:591-595.
63. Diskin R., Marcovecchio P.M., Bjorkman P.J. Structure of a Clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Nat Struct Mol Biol 2010, 17:608-613.
64. Sun Z.-Y., Oh K.G., Kim M., Yu J., Brusic V., Song L., Qiao X., Wang J.H., Wagner G., Reinherz E.L. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 2008, 28:52-63.
65. Ofek G., Tang M., Sambor A., Katinger H., Mascola J.R., Wyatt R., Kwong P.D. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004, 78:10724-10737.
66. Zwick M.B., Komori H.K., Stanfield R.L., Church S., Wang M., Parren P.W., Kunert R., Katinger H., Wilson I.A., Burton D.R. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol 2004, 78:3155-3161.
67. Cardoso R.M., Zwick M.B., Stanfield R.L., Kunert R., Binley J.M., Katinger H., Burton D.R., Wilson I.A. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005, 22:163-173.
68. Trkola A., Kuster H., Rusert P., Joos B., Fischer M., Leemann C., Manrique A., Huber M., Rehr M., Oxenius A., et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005, 11:615-622.
69. Ferrantelli F., Buckley K.A., Rasmussen R.A., Chalmers A., Wang T., Li P.L., Williams A.L., Hofmann-Lehmann R., Montefiori D.C., Cavacini L.A., et al. Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. Virology 2007, 358:69-78.
70. Montero M., van Houten N.E., Wang X., Scott J.K. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev 2008, 72:54-84.
71. Lerner R.A. Rare antibodies from combinatorial libraries suggests an S.O.S. Component of the human immunological repertoire. Mol Biosyst 2011, 108:5560-5565.
72. Dennison S.M., Anasti K., Scearce R.M., Sutherland L., Parks R., Xia S.M., Liao H.X., Gorny M.K., Zolla-Pazner S., Haynes B.F., Alam S.M. Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens. J Virol 2011, 85:1340-1347.
73. Guenaga J., Dosenovic P., Ofek G., Baker D., Schief W.R., Kwong P.D., Karlsson Hedestam G.B., Wyatt R.T. Heterologous epitope-scaffold prime: boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS ONE 2011, 6:e16074.
74. Dennison S.M., Jaeger F., Anasti K., Sutherland L., Bowman C., Parks R., Santra S., Shen S., Tomaras G., Montefiori D., et al. Induction of antibodies with specificity for gp41 neutralizing epitopes by membrane anchored gp41 immunogens. AIDS Res Hum Retroviruses 2010, 26. A-5.10.